TREATING EPHRIN RECEPTOR A2 (EPHA2) POSITIVE CANCER WITH TARGETED DOCETAXEL-GENERATING NANO-LIPOSOME COMPOSITIONS

• 收藏
• 分享

专利权人:

MERRIMACK PHARMACEUTICALS; INC

发明人:

DRUMMOND, DARYL C.,KAMOUN, WALID

申请号：

CA3016383

公开号：

CA3016383A1

申请日:

2017.03.16

申请国别(地区):

CA

年份:

2017

代理人:

摘要：

EphA2 targeted doxorubicin generating nano-liposomes are useful in the treatment of cancer overexpressing EphA2, alone or in combination with chemotherapeutic agents such as gemcitabine or carboplatin.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/